Your browser doesn't support javascript.
loading
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.
Nguyen, Bastien; Fong, Christopher; Luthra, Anisha; Smith, Shaleigh A; DiNatale, Renzo G; Nandakumar, Subhiksha; Walch, Henry; Chatila, Walid K; Madupuri, Ramyasree; Kundra, Ritika; Bielski, Craig M; Mastrogiacomo, Brooke; Donoghue, Mark T A; Boire, Adrienne; Chandarlapaty, Sarat; Ganesh, Karuna; Harding, James J; Iacobuzio-Donahue, Christine A; Razavi, Pedram; Reznik, Ed; Rudin, Charles M; Zamarin, Dmitriy; Abida, Wassim; Abou-Alfa, Ghassan K; Aghajanian, Carol; Cercek, Andrea; Chi, Ping; Feldman, Darren; Ho, Alan L; Iyer, Gopakumar; Janjigian, Yelena Y; Morris, Michael; Motzer, Robert J; O'Reilly, Eileen M; Postow, Michael A; Raj, Nitya P; Riely, Gregory J; Robson, Mark E; Rosenberg, Jonathan E; Safonov, Anton; Shoushtari, Alexander N; Tap, William; Teo, Min Yuen; Varghese, Anna M; Voss, Martin; Yaeger, Rona; Zauderer, Marjorie G; Abu-Rustum, Nadeem; Garcia-Aguilar, Julio; Bochner, Bernard.
Affiliation
  • Nguyen B; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer
  • Fong C; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer
  • Luthra A; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer
  • Smith SA; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer
  • DiNatale RG; Molecular Pharmacology Program, Sloan Kettering Institute, New York, NY, USA; Urology and Renal Transplantation Service, Virginia Mason Medical Center, Seattle, WA, USA.
  • Nandakumar S; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer
  • Walch H; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer
  • Chatila WK; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer
  • Madupuri R; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer
  • Kundra R; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer
  • Bielski CM; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Medical College at Cornell University, New York, NY, USA.
  • Mastrogiacomo B; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer
  • Donoghue MTA; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Boire A; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Neurology and Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Chandarlapaty S; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Ganesh K; Molecular Pharmacology Program, Sloan Kettering Institute, New York, NY, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Harding JJ; Weill Medical College at Cornell University, New York, NY, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Iacobuzio-Donahue CA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Razavi P; Weill Medical College at Cornell University, New York, NY, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Reznik E; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer
  • Rudin CM; Molecular Pharmacology Program, Sloan Kettering Institute, New York, NY, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Zamarin D; Weill Medical College at Cornell University, New York, NY, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Abida W; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Abou-Alfa GK; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Aghajanian C; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Cercek A; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Chi P; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Feldman D; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Ho AL; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Iyer G; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Janjigian YY; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Morris M; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Motzer RJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • O'Reilly EM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Postow MA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Raj NP; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Riely GJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Robson ME; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Rosenberg JE; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Safonov A; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Shoushtari AN; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Tap W; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Teo MY; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Varghese AM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Voss M; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Yaeger R; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Zauderer MG; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Abu-Rustum N; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Garcia-Aguilar J; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Bochner B; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Cell ; 185(3): 563-575.e11, 2022 02 03.
Article in En | MEDLINE | ID: mdl-35120664
ABSTRACT
Metastatic progression is the main cause of death in cancer patients, whereas the underlying genomic mechanisms driving metastasis remain largely unknown. Here, we assembled MSK-MET, a pan-cancer cohort of over 25,000 patients with metastatic diseases. By analyzing genomic and clinical data from this cohort, we identified associations between genomic alterations and patterns of metastatic dissemination across 50 tumor types. We found that chromosomal instability is strongly correlated with metastatic burden in some tumor types, including prostate adenocarcinoma, lung adenocarcinoma, and HR+/HER2+ breast ductal carcinoma, but not in others, including colorectal cancer and high-grade serous ovarian cancer, where copy-number alteration patterns may be established early in tumor development. We also identified somatic alterations associated with metastatic burden and specific target organs. Our data offer a valuable resource for the investigation of the biological basis for metastatic spread and highlight the complex role of chromosomal instability in cancer progression.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Genomics / High-Throughput Nucleotide Sequencing / Neoplasm Metastasis Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male Language: En Journal: Cell Year: 2022 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Genomics / High-Throughput Nucleotide Sequencing / Neoplasm Metastasis Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male Language: En Journal: Cell Year: 2022 Document type: Article
...